Intensive lipid-lowering therapy is proven to reduce the risk of recurrent stroke, heart attacks, and other vascular events in patients with a history of ischemic stroke or transient ischemic attack (TIA). This therapy significantly lowers both fatal and nonfatal strokes, as well as coronary and peripheral events when compared with placebo, based on SPARCL Trial. Prioritizing lipid management is essential for poststroke prevention and long-term cardiovascular protection.